Full Text View
Tabular View
No Study Results Posted
Related Studies
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
This study is enrolling participants by invitation only.
Study NCT00546117   Information provided by Washington University School of Medicine
First Received: October 17, 2007   No Changes Posted

October 17, 2007
October 17, 2007
October 2007
 
Resolution of middle ear fluid by pneumatic otoscopy [ Time Frame: 2 months ]
Same as current
No Changes Posted
acoustic reflectometry, tympanometry, reflux symptom questionnaires [ Time Frame: 2 months ]
Same as current
 
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
 

This study is being done to see if reflux of stomach fluid might be a cause of chronic fluid in the ears. Our hypothesis is that treatment with an anti-reflux medication (lansoprazole) will increase the rate of resolution of chronic middle ear fluid in children.

This study is being done to see if reflux of stomach fluid might be a cause of fluid in the ears. Earlier studies have found pepsin or pepsinogen, a component of stomach fluid, in the middle ear fluid of many children with chronic middle ear fluid. Anti-reflux medicines called proton pump inhibitors (PPI) reduce the acidity of the contents of the stomach and the activity of pepsin or pepsinogen. We are studying the effectiveness of a PPI called lansoprazole (Prevacid™) in reducing fluid in the ears. If lansoprazole is able to reduce the fluid in the middle ear, this tells us that the reflux of gastric acid into the esophagus and into the ear canal may be causing middle ear fluid.

 
Interventional
Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Otitis Media With Effusion
Drug: lansoprazole
  • Experimental: Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
  • Placebo Comparator: Placebo SoluTab once daily for 2 months

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Enrolling by invitation
144
October 2008
 

Inclusion Criteria:

  • History of chronic otitis media with effusion meeting clinical indications for tympanostomy tubes placement, defined as the presence of middle ear fluid on physical exam for at least 3 months, in at least one ear.

Exclusion Criteria:

  • Past medical history or concurrent conditions known to increase the incidence of either recurrent otitis media or otitis media with effusion or gastroesophageal reflux disease, including cleft palate, neurological delay, cerebral palsy, Down syndrome, velocardiofacial syndrome, and primary ciliary dyskinesia.
  • Children with structural abnormalities of the tympanic membranes, such as cholesteatoma, deep retraction pockets, and atelectasis of the tympanic membrane. These abnormalities would require placement of tympanostomy tubes in standard clinical practice.
  • Children weighing less than 10 kilograms, due to the lower weight limit for standard Prevacid™ dosing
Both
2 Years to 12 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00546117
 
HRPO# 07-0762
Washington University School of Medicine
  • Doris Duke Charitable Foundation
  • TAP Pharmaceutical Products Inc.
Principal Investigator: Judith EC Lieu, MD Washington University School of Medicine
Washington University School of Medicine
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP